Abeona Therapeutics

Abeona Therapeutics company information, Employees & Contact Information

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Prademagene zamikeracel (pz-cel) is Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa. The Company’s fully integrated cell and gene therapy cGMP manufacturing facility served as the manufacturing site for pz-cel used in its Phase 3 VIITAL™ trial, and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.

Company Details

Employees
192
Founded
-
Address
6555 Carnegie Avenue, Cleveland,oh 44103,united States
Phone
(216)287-5408
Email
tm****@****ics.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Cleveland, OH
Looking for a particular Abeona Therapeutics employee's phone or email?

Abeona Therapeutics Questions

News

Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, - GlobeNewswire

Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, GlobeNewswire

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Yahoo Finance

Biotech Investor Alert: Abeona Therapeutics Announces Double Conference Presentations in September 2025 - Stock Titan

Biotech Investor Alert: Abeona Therapeutics Announces Double Conference Presentations in September 2025 Stock Titan

Abeona Therapeutics® and Children's Hospital Colorado - GlobeNewswire

Abeona Therapeutics® and Children's Hospital Colorado GlobeNewswire

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder - Yahoo Finance

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder Yahoo Finance

Abeona Therapeutics' ABO-503 Gene Therapy for X-Linked Retinoschisis Selected for FDA Rare Disease Endpoint Advancement Pilot Program - Quiver Quantitative

Abeona Therapeutics' ABO-503 Gene Therapy for X-Linked Retinoschisis Selected for FDA Rare Disease Endpoint Advancement Pilot Program Quiver Quantitative

FDA Approves Abeona Therapeutics' Epidermolysis Bullosa Gene Therapy Pz-Cel - CGTLive®

FDA Approves Abeona Therapeutics' Epidermolysis Bullosa Gene Therapy Pz-Cel CGTLive®

Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates - GlobeNewswire

Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates GlobeNewswire

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences - GlobeNewswire

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences GlobeNewswire

Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million - GlobeNewswire

Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million GlobeNewswire

Abeona Therapeutics® Announces Option Exercise by Beacon - GlobeNewswire

Abeona Therapeutics® Announces Option Exercise by Beacon GlobeNewswire

Abeona Therapeutics® added to Membership of U.S. Small-cap - GlobeNewswire

Abeona Therapeutics® added to Membership of U.S. Small-cap GlobeNewswire

Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million - GlobeNewswire

Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million GlobeNewswire

Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates - GlobeNewswire

Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates GlobeNewswire

Abeona Therapeutics® Reports Full Year 2024 Financial - GlobeNewswire

Abeona Therapeutics® Reports Full Year 2024 Financial GlobeNewswire

Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program - GlobeNewswire

Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program GlobeNewswire

15,500 Restricted Shares: Abeona Therapeutics Grants Stock Awards to Seven New Hires Under Nasdaq Rule - Stock Titan

15,500 Restricted Shares: Abeona Therapeutics Grants Stock Awards to Seven New Hires Under Nasdaq Rule Stock Titan

Biotech Firm Abeona Therapeutics Awards 19,420 Restricted Shares in Key Employee Inducement Program - Stock Titan

Biotech Firm Abeona Therapeutics Awards 19,420 Restricted Shares in Key Employee Inducement Program Stock Titan

Abeona Therapeutics Expands Team with 21 New Hires, Grants Nearly 50K Restricted Shares - Stock Titan

Abeona Therapeutics Expands Team with 21 New Hires, Grants Nearly 50K Restricted Shares Stock Titan

Abeona Therapeutics Appoints James A. Gow as SVP, Head of Clinical | ABEO Stock News - Stock Titan

Abeona Therapeutics Appoints James A. Gow as SVP, Head of Clinical | ABEO Stock News Stock Titan

Abeona Therapeutics Inc. Advances pz-cel BLA Review with FDA, Anticipates Commercial Launch for RDEB Treatment by Q3 2025 - Quiver Quantitative

Abeona Therapeutics Inc. Advances pz-cel BLA Review with FDA, Anticipates Commercial Launch for RDEB Treatment by Q3 2025 Quiver Quantitative

FDA Accepts Abeona Therapeutics' BLA for Epidermolysis Bullosa Gene Therapy Pz-Cel - CGTLive®

FDA Accepts Abeona Therapeutics' BLA for Epidermolysis Bullosa Gene Therapy Pz-Cel CGTLive®

Children's Hospital Colorado named newest QTC for Abeona's FDA‑approved ZEVASKYN to treat RDEB - Stock Titan

Children's Hospital Colorado named newest QTC for Abeona's FDA‑approved ZEVASKYN to treat RDEB Stock Titan

Revolutionary Eye Gene Therapy: Beacon Licenses Abeona's AAV204 to Combat Blindness - Stock Titan

Revolutionary Eye Gene Therapy: Beacon Licenses Abeona's AAV204 to Combat Blindness Stock Titan

FDA Issues CRL for Abeona's Epidermolysis Bullosa Gene Therapy Pz-Cel - CGTLive®

FDA Issues CRL for Abeona's Epidermolysis Bullosa Gene Therapy Pz-Cel CGTLive®

Abeona Therapeutics and Beacon Therapeutics Announce - GlobeNewswire

Abeona Therapeutics and Beacon Therapeutics Announce GlobeNewswire

Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A (MPS IIIA) - Yahoo Finance

Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A (MPS IIIA) Yahoo Finance

Abeona Therapeutics Reports Second Quarter Financial Results - Yahoo Finance

Abeona Therapeutics Reports Second Quarter Financial Results Yahoo Finance

Abeona Therapeutics and Taysha Gene Therapies Enter into - GlobeNewswire

Abeona Therapeutics and Taysha Gene Therapies Enter into GlobeNewswire

Abeona Therapeutics Receives Rare Pediatric Disease - GlobeNewswire

Abeona Therapeutics Receives Rare Pediatric Disease GlobeNewswire

Top Abeona Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant